FDA approves Roche's Wilserdly combination for advanced breast cancer
The FDA approved Roche's Wilserdly with everolimus for adults with previously treated ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. In ESR1-mutated patients, the combination reduced the risk of disease progression or death by 62% versus standard endocrine therapy with everolimus.
1. FDA approval
The FDA approved Roche's Wilserdly with everolimus for adults with previously treated ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. The combination reduced the risk of disease progression or death by 62% versus standard endocrine therapy with everolimus in ESR1-mutated patients.
2. Separate review
A separate FDA review of Wilserdly for adjuvant breast cancer treatment has a decision deadline of November 30, 2026.





